Humasis Co. Ltd. (KOSDAQ:205470)
South Korea · Delayed Price · Currency is KRW 1,437.00
+39.00 (2.79%)
Aug 8, 2025, 3:30 PM KST
Humasis Revenue
Humasis had revenue of 6.16B KRW in the quarter ending March 31, 2025, with 229.81% growth. This brings the company's revenue in the last twelve months to 29.71B, up 140.71% year-over-year. In the year 2024, Humasis had annual revenue of 25.41B with 83.79% growth.
Revenue (ttm)
29.71B
Revenue Growth
+140.71%
P/S Ratio
5.32
Revenue / Employee
424.41M
Employees
70
Market Cap
158.19B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 25.41B | 11.59B | 83.79% |
| Dec 31, 2023 | 13.83B | -457.45B | -97.07% |
| Dec 31, 2022 | 471.27B | 149.44B | 46.44% |
| Dec 31, 2021 | 321.83B | 276.11B | 603.96% |
| Dec 31, 2020 | 45.72B | 36.57B | 399.61% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4,898.69B |
| Celltrion | 3,662.23B |
| ALTEOGEN | 151.65B |
| Yuhan | 2,114.76B |
| SK Biopharmaceuticals | 578.00B |
| Peptron | 4.30B |
| HLB Co., Ltd. | 74.64B |
| PharmaResearch | 392.31B |